|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500104796 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-24 08:32:33 |
|
注册时间: Date of Registration: |
2025-06-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
一项血嗜酸性粒细胞预测慢阻肺患者肺康复干预后心理改善的前瞻性随机对照临床研究 |
|
Public title: |
A prospective randomized controlled clinical study on the prediction of psychological improvement in patients with chronic obstructive pulmonary disease (COPD) after pulmonary rehabilitation intervention by blood eosinophils |
|
注册题目简写: |
嗜酸性粒细胞预测慢阻肺患者肺康复后心理改善 |
|
English Acronym: |
Eosinophils predict psychological improvement in patients with chronic obstructive pulmonary disease after pulmonary rehabilitation |
|
研究课题的正式科学名称: |
一项血嗜酸性粒细胞预测慢阻肺患者肺康复干预后心理改善的前瞻性随机对照临床研究 |
|
Scientific title: |
A prospective randomized controlled clinical study on the prediction of psychological improvement in patients with chronic obstructive pulmonary disease (COPD) after pulmonary rehabilitation intervention by blood eosinophils |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
275735 |
|
申请注册联系人: |
程业杰 |
研究负责人: |
程业杰 |
|
Applicant: |
Yejie Cheng |
Study leader: |
Yejie Cheng |
|
申请注册联系人电话: Applicant telephone: |
+86 133 6831 0427 |
研究负责人电话:
Study leader's |
+86 68310427 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
838438470@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
838438470@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
重庆市长寿区人民医院 |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
重庆市长寿区渡舟街道站北路888号 |
研究负责人通讯地址: |
重庆市长寿区渡舟街道站北路888号 |
|
Applicant address: |
No. 888, Zhanbei Road, Duzhou Sub-district, Chongqing City, Changshou District |
Study leader's address: |
No. 888, Zhanbei Road, Duzhou Sub-district, Chongqing City, Changshou District |
|
申请注册联系人邮政编码: Applicant postcode: |
401220 |
研究负责人邮政编码: Study leader's postcode: |
|
|
申请人所在单位: |
重庆市长寿区人民医院 |
||
|
Applicant's institution: |
Chongqing Changshou District People's Hospital |
||
|
研究负责人所在单位: |
重庆市长寿区人民医院 |
||
|
Affiliation of the Leader: |
Chongqing Changshou District People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
科自伦审第2025-032-001号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆市长寿区人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Chongqing Changshou District People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-04-30 00:00:00 | ||
|
伦理委员会联系人: |
刘建平 |
||
|
Contact Name of the ethic committee: |
Jianping Liu |
||
|
伦理委员会联系地址: |
重庆市长寿区渡舟街道站北路888号 |
||
|
Contact Address of the ethic committee: |
No. 888, Zhanbei Road, Duzhou Sub-district, Chongqing City, Changshou District |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 4040 1521 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
1170211290@qq.com |
|
研究实施负责(组长)单位: |
重庆市长寿区人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Medical Ethics Committee of Chongqing Changshou District People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市长寿区渡舟街道站北路888号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 888, Zhanbei Road, Duzhou Sub-district, Chongqing City, Changshou District |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-raised |
||||||||||||||||||||||
|
研究疾病: |
慢性阻塞性肺病 |
||||||||||||||||||||||
|
Target disease: |
chronic obstructive pulmonary disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究旨在评估血EOS增高的COPD患者在接受肺康复治疗后,焦虑、抑郁等心理状况的改善情况是否更明显,进而探究血EOS能否作为肺康复后心理状况改善的预测指标。若研究结果证实上述推测,将为COPD患者的个性化肺康复治疗提供新的生物标记物参考,有助于更精准地评估患者肺康复效果,优化康复方案,提高患者的心理健康水平和生活质量。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to evaluate whether the improvement of psychological conditions such as anxiety and depression in COPD patients with elevated blood EOS is more obvious after receiving pulmonary rehabilitation treatment, and further explore whether blood EOS can be used as a predictive indicator for the improvement of psychological conditions after pulmonary rehabilitation. If the research results confirm the above speculation, it will provide new biomarker references for personalized pulmonary rehabilitation treatment of COPD patients, which is conducive to more accurately evaluating the pulmonary rehabilitation effect of patients, optimizing the rehabilitation plan, and improving the mental health level and quality of life of patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
从重庆市长寿区人民医院呼吸与危重症医学科门诊及住院患者中纳入100-200例COPD患者,随机分为康复组和常规治疗组,康复组行8周期远程PR,常规治疗组进行一般的治疗和护理。评估PR后运动能力(6MWT)、呼吸困难(mMRC)、生活质量(CAT)、医院焦虑抑郁评分表(HADS-A/HDAS-D)、抑郁筛查量表(PHQ-9)、焦虑症筛查量表(GAD-7)、贝克抑郁量表(BDI-II)、贝克焦虑量表(BAI)。基线评估后,合格的患者被随机分配到康复组(RG)和常规治疗组(CG),根据外周血EOS计数将RG组分为EOS ≥ 150 cells/μL组和EOS < 150 cells/μL组。门诊指导后,RG组患者按照最新指南进行为期8周的远程PR计划,PR后进行为期6月的随访。CG组接受常规治疗,包括药物治疗、健康教育、以及医生的戒烟建议。 PR完全根据个人需求量身定制,包括有远程监督的呼吸训练、运动训练、教育、营养干预和心理支持。所有运动训练都是在没有负重的情况下开始的,运动训练持续20-30 min,每周2-3次。使用Borg呼吸困难评分来调节运动, 运动强度根据患者进展而增加,有氧运动训练中指脉血氧饱和度(SpO2)应始终大于等于88%,如果患者运动中SpO2<88%或下降超过4%,应停止训练,并补充氧疗。 在基线、8周、12周、20周和32周分别评估运动能力(6MWT)、呼吸功能(mMRC)、生活质量(CAT评分)、心理状况(医院焦虑抑郁评分表、抑郁筛查量表、焦虑症筛查量表、贝克抑郁量表、贝克焦虑量表)。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1: 年龄≥40岁; 2: 根据GOLD指南诊断慢性阻塞性肺疾病,吸入支气管扩张剂后1秒用力呼气量/用力肺活量(FEV1/FVC比值)<70%; 3: 病情恶化稳定 (呼吸系统症状没有恶化,或急性加重者能耐受相关训练)。 |
||||||||||||||||||||||
|
Inclusion criteria |
1: Age >=40 years old; 2: According to the GOLD guidelines for diagnosing chronic obstructive pulmonary disease, the forced expiratory volume in one second/forced vital capacity (FEV1/FVC ratio) after inhaling bronchodilators is less than 70%; 3: The condition has deteriorated and stabilized (those with no deterioration of respiratory symptoms or acute exacerbation can tolerate relevant training). |
||||||||||||||||||||||
|
排除标准: |
1: 3个月内接受肺部手术治疗的患者,其他肺部疾病(哮喘、肺纤维化、支气管扩张、肺结核); 2: 心律失常、近期不稳定型心绞痛发作或急性心肌梗死,未控制的高血压; 3: 活动性出血,不稳定性骨折,由于神经肌肉疾病造成的运动困难; 4: 传染性疾病; 5: 严重认知障碍和精神行为异常,缺乏动力、依从性差等其他原因不能配合肺康复。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1: Patients who have undergone lung surgery within 3 months and have other lung diseases (asthma, pulmonary fibrosis, bronchiectasis, tuberculosis); 2: Arrhythmia, recent unstable angina pectoris attack or acute myocardial infarction, uncontrolled hypertension; 3: Active bleeding, unstable fractures, and movement difficulties caused by neuromuscular diseases; 4: Infectious diseases; 5: Severe cognitive impairment, abnormal mental behavior, lack of motivation, poor compliance and other reasons prevent cooperation with pulmonary rehabilitation. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-06-01 00:00:00至 To 2027-05-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-07-01 00:00:00 至 To 2027-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
区组随机,由专业医护人员使用区组随机分组的方法分组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The groups were grouped by professional medical staff using the method of block randomization |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲,对评估者隐藏分组 |
|
Blinding: |
Single-blind, with the groups concealed from the evaluators |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2027年5月,病例报告表(CRF) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
In May 2027, Case Report Form (CRF) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用标准化病例记录表(CRF)和电子数据采集(EDC)系统,由专业医护人员记录: 基线资料(人口学特征、临床指标) 随访数据(6MWT、mMRC、CAT评分) 心理量表评分(HADS、PHQ-9、GAD-7等) 不良事件报告 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Standardized Case Record Forms (CRF) and Electronic Data Acquisition (EDC) systems were adopted, and the records were made by professional medical staff: Baseline data (demographic characteristics, clinical indicators) Follow-up data (6MWT, mMRC, CAT score) Psychological scale scores (HADS, PHQ-9, GAD-7, etc.) Adverse event report |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |